| Field | Specification |
|---|---|
| Target | |
| Alternative names | Proliferating cell nuclear antigen; PCNA; Cyclin; PCNA |
| UniProt # | |
| Host | |
| Clonality | |
| Isotype | |
| Reactivity | |
| Applications | |
| Immunogen | E.coli-derived human PCNA recombinant protein (Position: M1-S261). |
| Molecular weight | |
| Purification | |
| Reconstitution | |
| Cellular localization | |
| Concentration | |
| Form | Lyophilized |
| Storage | |
| Catalog no. (Mfr.) | |
| Main SKU |
Product Overview
This rabbit polyclonal antibody recognizes DNA sliding clamp PCNA in human, mouse and rat samples and is validated for Western blot, IHC, ICC/IF, flow cytometry and ELISA. The predicted molecular weight is 28.8 kDa, and the supplier reports an observed band at about 36 kDa.
PCNA (proliferating cell nuclear antigen) is a ring-shaped DNA clamp that encircles DNA and tethers polymerases δ and ε for processive replication. It also serves as a platform for many repair and damage-tolerance factors and is a classic marker of proliferating cells.
| Target | DNA sliding clamp PCNA (gene PCNA; UniProt P12004, human) |
|---|---|
| Host / Clonality / Isotype | Rabbit / Polyclonal / Rabbit IgG |
| Reactivity | Human, Mouse, Rat |
| Form | Lyophilized |
| Formulation | Per vial: 4 mg trehalose; 0.9 mg NaCl; 0.2 mg Na2HPO4 |
| Calculated MW | 28.8 kDa |
| Observed MW | 36 kDa |
| Storage | As supplied: −20 °C for up to 12 months from receipt. After reconstitution: 4 °C for up to 1 month, or aliquot and keep at −20 °C for up to 6 months. Avoid repeated freeze–thaw cycles. |
Validated Applications
| Western blot | 0.25–0.5 µg/mL (Human, Mouse, Rat) |
|---|---|
| IHC (paraffin sections) | 2–5 µg/mL (Human, Rat) |
| Immunocytochemistry / Immunofluorescence | 5 µg/mL (Human) |
| Flow cytometry (fixed cells) | 1–3 µg/1×106 cells (Human) |
| ELISA | 0.1–0.5 µg/mL |
Samples with a confirmed band (WB): human HeLa cells, human MCF-7 cells, human 293T cells, human HepG2 cells, rat PC-12 cells, mouse NIH/3T3 cells.
Recommended loading (WB): 20–40 µg of total protein per lane.
Conditions in the example images (WB): 5–20% gradient SDS-PAGE under reducing conditions, 30 µg lysate per lane, transfer to nitrocellulose membrane, blocking in 5% non-fat milk, primary antibody at 0.5 µg/mL overnight at 4 °C, HRP-conjugated secondary antibody at 1:5000, ECL detection.
Samples with confirmed staining (IHC): human breast cancer tissue, human colorectal adenocarcinoma tissue, human tonsil tissue, human papillary thyroid carcinoma tissue, human glioblastoma tissue, human liver cancer tissue, rat colon tissue.
Recommended antigen retrieval: heat-mediated, in TE buffer (pH 9.0); citrate buffer (pH 6.0) can be used instead.
Conditions in the example images (IHC): heat-mediated antigen retrieval in EDTA buffer (pH 8.0).
Samples with confirmed staining (ICC/IF): A431 cells.
Samples with a confirmed signal (flow cytometry): 293T cells.
Immunogen
Recombinant human PCNA fragment (Met1–Ser261), expressed in E. coli.
Reactivity Notes
The supplier lists reactivity with human, mouse and rat. UniProt places DNA sliding clamp PCNA in the nucleus. The samples tested by the supplier (listed above) are a practical starting point for positive controls.
Safety
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
Di Wu et al. (2024) Tailoring Carrier-Free Nanoparticles based on Natural Small Molecule Assembly for Synergistic Anti-tumor Efficacy. Asian Journal of Pharmaceutical Sciences. 10.1016/j.ajps.2024.100992
Chunhui Lai et al. (2018) The enhanced antitumor-specific immune response with mannose- and CpG-ODN-coated liposomes delivering TRP2 peptide. Theranostics. 10.7150/thno.22056
Hanliang Sun et al. (2025) 5-Methylcytosine-modified circRNA-CCNL2 regulates vascular remdeling in hypoxic pulmonary hypertension through binding to FXR2. International Journal of Biological Macromolecules. 10.1016/j.ijbiomac.2025.139638
Xiaobing Wang et al. (2018) Enhanced drug delivery using sonoactivatable liposomes with membrane-embedded porphyrins. Journal of Controlled Release. 10.1016/j.jconrel.2018.07.048
Shuting Xu et al. (2017) Supramolecular cisplatin-vorinostat nanodrug for overcoming drug resistance in cancer synergistic therapy. Journal of Controlled Release. 10.1016/j.jconrel.2017.09.007
Yufeng You et al. (2016) Nanoparticle-enhanced synergistic HIFU ablation and transarterial chemoembolization for efficient cancer therapy. Nanoscale. 10.1039/C5NR08292G
Xinbo Wei et al. (2023) Hepatocyte-targeted delivery using oleanolic acid-loaded liposomes for enhanced hepatocellular carcinoma therapy. Biomaterials Science. 10.1039/D3BM00261F
Wang Yang et al. (2018) Synergistic inhibitory effects of capsaicin combined with cisplatin on human osteosarcoma in culture and in xenografts. Journal of Experimental & Clinical Cancer Research. 10.1186/s13046-018-0922-0
Ma Cui et al. (2026) Super enhancer-driven LINC01013 mediates hypoxia-induced mitochondrial dysfunction by HSPA9 to determine pulmonary arterial smooth muscle cell fate. Cellular and Molecular Life Sciences. 10.1007/s00018-025-06071-3
Xu Liangliang et al. (2019) CircSETD3 (Hsa_circ_0000567) acts as a sponge for microRNA-421 inhibiting hepatocellular carcinoma growth. Journal of Experimental & Clinical Cancer Research. 10.1186/s13046-019-1041-2
